Literature DB >> 31206759

A parametric meta-analysis.

Chang Yu1, Daniel Zelterman2.   

Abstract

In a meta-analysis, we assemble a sample of independent, nonidentically distributed p-values. The Fisher's combination procedure provides a chi-squared test of whether the p-values were sampled from the null uniform distribution. After rejecting the null uniform hypothesis, we are faced with the problem of how to combine the assembled p-values. We first derive a distribution for the p-values. The distribution is parameterized by the standardized mean difference (SMD) and the sample size. It includes the uniform as a special case. The maximum likelihood estimate (MLE) of the SMD can then be obtained from the independent, nonidentically distributed p-values. The MLE can be interpreted as a weighted average of the study-specific estimate of the effect size with a shrinkage. The method is broadly applicable to p-values obtained in the maximum likelihood framework. Simulation studies show that our method can effectively estimate the effect size with as few as 6 p-values in the meta-analyses. We also present a Bayes estimator for SMD and a method to account for publication bias. We demonstrate our methods on several meta-analyses that assess the potential benefits of citicoline for patients with memory disorders or patients recovering from ischemic stroke.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Bayesian estimator; citicoline; distribution of p-values; standardized mean difference

Year:  2019        PMID: 31206759      PMCID: PMC6688941          DOI: 10.1002/sim.8278

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  16 in total

1.  r equivalent: A simple effect size indicator.

Authors:  Robert Rosenthal; Donald B Rubin
Journal:  Psychol Methods       Date:  2003-12

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 3.  Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.

Authors:  M Fioravanti; M Yanagi
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

4.  A simple effect size indicator for two-group comparisons? A comment on r equivalent.

Authors:  Helena Chmura Kraemer
Journal:  Psychol Methods       Date:  2005-12

5.  Some properties of r equivalent: a simple effect size indicator.

Authors:  Louis M Hsu
Journal:  Psychol Methods       Date:  2005-12

6.  Nonparametric bayesian estimation of positive false discovery rates.

Authors:  Yongqiang Tang; Subhashis Ghosal; Anindya Roy
Journal:  Biometrics       Date:  2007-05-14       Impact factor: 2.571

7.  Choosing an optimal method to combine P-values.

Authors:  Sungho Won; Nathan Morris; Qing Lu; Robert C Elston
Journal:  Stat Med       Date:  2009-05-15       Impact factor: 2.373

8.  Optimally weighted Z-test is a powerful method for combining probabilities in meta-analysis.

Authors:  D V Zaykin
Journal:  J Evol Biol       Date:  2011-05-23       Impact factor: 2.411

9.  Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial).

Authors:  Antoni Dávalos; José Alvarez-Sabín; José Castillo; Exuperio Díez-Tejedor; Jose Ferro; Eduardo Martínez-Vila; Joaquín Serena; Tomás Segura; Vitor T Cruz; Jaime Masjuan; Erik Cobo; Julio J Secades
Journal:  Lancet       Date:  2012-06-11       Impact factor: 79.321

10.  A comparative review of estimates of the proportion unchanged genes and the false discovery rate.

Authors:  Per Broberg
Journal:  BMC Bioinformatics       Date:  2005-08-08       Impact factor: 3.169

View more
  1 in total

1.  Application of Citicoline in Neurological Disorders: A Systematic Review.

Authors:  Patryk Jasielski; Faustyna Piędel; Mikołaj Piwek; Agata Rocka; Véronique Petit; Konrad Rejdak
Journal:  Nutrients       Date:  2020-10-12       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.